Information Provided By: 
Fly News Breaks for July 11, 2019
NAVB
Jul 11, 2019 | 08:11 EDT
Maxim analyst Jason McCarthy initiated Navidea with a Buy rating and a price target of $2, saying the Tc99m-tilmanocept immunodiagnostic platform that the company is developing has the potential to change the diagnostic paradigm across several larger therapeutic areas, starting with rheumatoid arthritis, or RA. With a phase 2B trial in RA already underway, the analyst expects the focus to turn to the interim data expected in the second half of this year and the completion of the trial in 2020.
News For NAVB From the Last 2 Days
There are no results for your query NAVB
